LRP8 and Alzheimer disease: ASO therapies targeting APOE receptors have also been tested in AD mouse models and treatment of AD mouse with an anti-APOER2 oligonucleotide resulted in increased synaptic function and improved learning and memory functions (Hinrich et al., 2016).